Jacobs Levy Equity Management
AVIR icon

Jacobs Levy Equity Management’s Atea Pharmaceuticals AVIR Stock Holding History

Jacobs Levy Equity Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Hold
43,104
– – ﹤0.01% 901
2025
Q4 		$154K Sell
43,104
-355,319
-89% -$1.13M ﹤0.01% 897
2025
Q3 		$1.16M Buy
398,423
+107,963
+37% +$369K ﹤0.01% 688
2025
Q2 		$1.05M Buy
290,460
+172,293
+146% +$514K ﹤0.01% 748
2025
Q1 		$353K Sell
118,167
-272,732
-70% -$851K ﹤0.01% 961
2024
Q4 		$1.31M Sell
390,899
-118,572
-23% -$394K ﹤0.01% 676
2024
Q3 		$1.71M Sell
509,471
-55,427
-10% -$201K 0.01% 635
2024
Q2 		$1.87M Sell
564,898
-108,086
-16% -$403K 0.01% 613
2024
Q1 		$2.72M Buy
672,984
+122,447
+22% +$479K 0.01% 548
2023
Q4 		$1.68M Sell
550,537
-2,840
-0.5% -$8.6K 0.01% 632
2023
Q3 		$1.66M Sell
553,377
-11,395
-2% -$38.8K 0.01% 594
2023
Q2 		$2.11M Sell
564,772
-67,458
-11% -$253K 0.01% 554
2023
Q1 		$2.12M Buy
632,230
+133,172
+27% +$540K 0.01% 564
2022
Q4 		$2.4M Buy
499,058
+118,541
+31% +$600K 0.02% 518
2022
Q3 		$2.17M Sell
380,517
-51,921
-12% -$397K 0.02% 541
2022
Q2 		$3.07M Buy
432,438
+278,833
+182% +$1.9M 0.02% 511
2022
Q1 		$1.11M Buy
+153,605
New +$1.04M 0.01% 739

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management's AVIR Position: Q1 2026 in Review

Jacobs Levy Equity Management held its Atea Pharmaceuticals (AVIR) position steady in Q1 2026 at 43,104 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

Jacobs Levy Equity Management first reported a position in AVIR in Q1 2022 and has held it in 17 quarters since. The position peaked at $3.07M in Q2 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Jacobs Levy Equity Management held 43,104 shares of Atea Pharmaceuticals worth $232K as of Q1 2026.
  • Jacobs Levy Equity Management left its Atea Pharmaceuticals share count unchanged in Q1 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #901 holding.
  • Jacobs Levy Equity Management first reported a position in Atea Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Jacobs Levy Equity Management's Atea Pharmaceuticals position peaked at $3.07M in Q2 2022.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.